Preclinical studies have shown that bacterial sepsis leads to increased expression of CTLA-4 on CD4+ and CD8+ T cells, and anti-CTLA-4 treatment exhibits dose-dependent reductions in CD4+ and CD8+ T lymphocyte apoptosis and improved survival (51, 55). The gene discussed is CD8A; the disease is bacterial infectious disease with sepsis.